Formation raises $600 million to fix AI's biotech bottleneck

Formation Bio has raised a $600 million drug development accelerator fund to help address AI's biotech bottleneck by acquiring molecules and drug programs. CEO Ben Liu explains that the startup aims to use AI and centralization to reduce clinical research organization costs and build a large pharmaceutical company. Each acquired company will operate as a NewCo with early successes eventually sold to Big Pharma. Open article →